Testimonials

Since Tri-Solfen^® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Country	Species	Patent
Australia	Sheep	Granted
Australia	Horses, Dogs, Lab animals	Granted
Australia	Cattle	Granted
Australia	Humans	Granted
New Zealand	Sheep, Cattle	Granted
New Zealand	Horses, Dogs, Lab animals	Granted
EU	Humans	Granted
EU	Pig, Sheep, Cattle	Granted
USA	Dogs, Horses, Lab animals	Granted
USA	Humans	Granted
USA	Pig, Sheep, Cattle	Granted
Canada	Horses, Dogs, Lab animals	Granted
Canada	Cattle, Pig	Granted
Canada	Humans	Granted

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Press Release

Australian life sciences company Medical Ethics announce a £3 million investment in Wales

May 22, 2018

Melbourne-based life science research and development company Medical Ethics has announced a direct investment of over £3 million in Wales over the next three years, making Cardiff its new base in the northern hemisphere.

Medical Ethics develop products that alleviate pain and minimise suffering associated with wounds and surgical procedures in animals. As a UK hub for life sciences expertise, Wales will provide the company with the ideal base to progress the development of its technology for humans.

Medical Ethics chose to invest in the UK for its expertise in a number of fields required for the commercialisation of the company’s technology. This includes regulatory affairs, manufacturing and clinical studies, tax subsidies and patent box incentives.

Currently Medical Ethics engages 18 independent service providers and consultants across the UK and has plans to expand its headcount. The company will also look to use other UK consultants and service providers as it addresses future regulatory and commercialisation requirements.

Medical Ethics has worked with the Department for International Trade (DIT) for two years, receiving advice, grant application assistance and introductions to key UK stakeholders including the Wales Wound Institute in Cardiff and Cardiff University, both of which the company now collaborates with. Without DIT’s support, the company would not have been able to identify these connections and would not have chosen the UK as a location for investment.

Allan Giffard, Managing Director, Medical Ethics said:
“For us, Wales was the obvious choice in the UK, especially given our sector – Life Sciences. Wales offers the skills, expertise and infrastructure for our business to thrive.

“Through DIT, we’ve been able to participate in the Global Entrepreneur Programme, enabling us to overcome a number of initial challenges. DIT, along with Innovate UK, also supported us with introductions to key experts including the Wales Wound Institute in Cardiff – an introduction which had a significant impact on our decision to choose the UK.

“When looking to expand internationally, we initially looked at a number of countries. However, we believe it would have been a more difficult process in these territories as we did not identify programmes that provide the same level of support we’ve been offered in the UK.”

Secretary of State for Wales Alun Cairns said:

“This announcement is testament to the strong appetite worldwide for investing in the UK, and is a real vote of confidence in Wales’ growing stature as a hotbed of life sciences expertise.

“It also showcases the commitment of the UK Government’s globally based network of trade experts to connect international investors with the right partners for their needs.

“Companies like Medical Ethics are helping to change health dynamics on a global scale and are quickly discovering that Wales is the go-to place to develop, manufacture and commercialise theirinnovations. The UK Government knows this and we have every intention of nurturing this industry for continued success in Wales and across the UK for years to come.”

Graham Stuart, Minister for Investment, Department for International Trade said:
“With a world-class network of universities, clinicians and industry professionals, Wales has a proven capacity in providing the expertise required by both domestic and international life science companies.

“It is now at the forefront of numerous pioneering developments across a wide variety of fields, from microbiology to pharmaceuticals. Medical Ethics’ investment in Wales is an affirmative nod to this and, as an international economic department, DIT is thrilled to have provided support.”

In the year 2016-17, DIT reported 85 investment projects in Wales, generating 2,581 jobs. Welsh companies exported more than £16.4bn of goods in 2017. The UK is the number one destination for health and life sciences Foreign Direct Investment in Europe.

Further information
• Contact the DIT Media and Digital Team on 020 7008 3333
• Follow us: @tradegovuk | gov.uk/dit
• Contact the Medical Ethics UK media team on 020 3727 1000.

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000

Testimonials

Patent Portfolio